EISAI CO

Eisai presented 3-year data on lecanemab at CTAD, showing increased patient benefit for early Alzheimer's disease, with 46% of low amyloid patients improving or maintaining cognition. Safety profile remained consistent, and early treatment initiation may positively impact disease progression. BioArctic's CEO, Gunilla Osswald, highlighted the long-term benefits and safety of lecanemab.

The Clarity AD trial showed that continuous lecanemab treatment for 3 years in early-stage Alzheimer's patients with low amyloid levels resulted in 46% improvement or no decline in symptoms, and 33% improvement on the CDR-SB scale. The findings suggest lecanemab may positively impact early AD progression. No new safety issues were reported, and treatment satisfaction was high among long-term users.

Eisai announced findings on anti-MTBR tau antibody E2814 at CTAD, showing reduced tau pathology biomarkers in DIAD patients, and initiated a Phase II study for early AD. E2814 targets tau propagation, stabilizing or reducing tau PET signals, suggesting inhibition of tau aggregation.

Eisai and Biogen presented lecanemab-irmb findings at CTAD, showing benefits of continued treatment for early Alzheimer's disease, including reduced disease progression and improved cognitive function. No new safety issues were reported, and a new method to quantify protofibrils in cerebrospinal fluid was developed, suggesting protofibrils' role in neurodegeneration. Long-term U.S. clinical studies indicated patient satisfaction with lecanemab, and the AHEAD 3-45 study, focusing on preclinical AD, completed enrollment in October 2024. Professor Lars Lannfelt received the CTAD Lifetime Achievement Award for his contributions to AD research.

Big Pharma companies like Pfizer, Johnson & Johnson, Biogen, and Novartis are focusing on new products to drive future growth amid patent cliffs and market challenges. Pfizer's Prevnar 20 holds strong market share despite competition, while J&J's Tremfya gains traction as Stelara faces biosimilar competition. Biogen's Leqembi struggles with uptake due to infrastructure challenges, and Novartis relies on new oncology drugs to offset patent expirations and price negotiations.

Eisai and Biogen present lecanemab findings at CTAD, showing benefits of continued treatment in early Alzheimer's disease, including reduced disease progression and improved patient satisfaction. A new testing method highlights the link between protofibrils and neurodegenerative biomarkers, suggesting protofibrils' role in AD neurodegeneration. The AHEAD study uses blood biomarkers to predict brain amyloid accumulation in preclinical AD, improving screening eligibility.

Lexeo Therapeutics' Phase I/II study of gene therapy LX1001 for Alzheimer’s associated with APOE4 variant shows promising interim results, with APOE2 found in cerebrospinal fluid and stabilization of amyloid pathology in most patients.

Recent advancements in HCC and BTC treatment include targeted therapy combinations like atezolizumab plus bevacizumab for HCC and durvalumab with gemcitabine and cisplatin for BTC, improving survival outcomes. Liquid biopsies and precision medicine are also transforming early detection and treatment options.

The 10th KoNECT International Conference (KIC) will be held from October 29-31 at Seoul Dragon City, featuring presentations on innovative drug development strategies by global pharmaceutical leaders. The event aims to foster a healthy clinical trial ecosystem and promote Korea's clinical trial capabilities globally.

Biogen reported Q3 revenue and adjusted earnings exceeding expectations, raising full-year profit guidance to $16.10-$16.60 per share. Sales of Alzheimer's drug Leqembi, new rare disease and depression treatments offset declines in MS products, contributing $67 million in Q3 sales.